 |
FDA Approval Activities for this Drug
Xalatan (latanoprost) ophthalmic solution, 0.005%, Pharmacia & Upjohn Company NDA 20-597/S28 & S29 7/14/03 7/28/03 |
Xalatan (latanoprost) ophthalmic solution, 0.005%, Pharmacia & Upjohn Company NDA 20-597/S-025 8/26/02 8/30/02 8/26/02 |
Xalatan (latanoprost) ophthalmic solution, 0.005%, Pharmacia & Upjohn Company NDA 20-597/S-023 11/26/01 4/28/03 |
Xalatan (latanoprost) ophthalmic solution, 0.005%, Pharmacia & Upjohn Company NDA 20-597/S-019 8/8/01 4/28/03 |
Xalatan (latanoprost) ophthalmic solution, 0.005%, Pharmacia & Upjohn Company NDA 20-597/S-010 | Latanoprost Ophthalmic Solution, Par Pharma, Tentative Approval | Latanoprost Ophthalmic Solution, Apotex, Inc., Tentative Approval | Xalatan (latanoprost) Ophthalmic Solution, Pharmacia and Upjohn Company, Labeling Revision | Latanoprost Ophthalmic Solution, Alcon Research, Ltd., Tentative Approval | Latanoprost Ophthalmic Solution, Bausch and Lomb, Inc., Tentative Approval | Latanoprost Ophthalmic Solution, PharmaForce, Inc., Tentative Approval | Latanoprost Ophthalmic Solution, Alcon Research, Ltd., Approval | Latanoprost Ophthalmic Solution, Apotex Inc., Approval | Latanoprost Ophthalmic Solution, Bausch and Lomb, Inc., Approval | Latanoprost Ophthalmic Solution, Mylan Pharmaceuticals Inc., Approval | Latanoprost Ophthalmic Solution, PharmaForce, Inc., Approval | Latanoprost Ophthalmic Solution, Paddock Laboratories, Inc., Approval | Xalatan, latanoprost, Solution/Drops; Ophthalmic, Pharmacia and Upjohn, Labeling Revision | Xalatan, latanoprost, Solution/Drops; Ophthalmic, Pharmacia and Upjohn, Manufacturing Change or Addition
^ FDA's latest approval appears at the bottom of this list. ^
|